Esperion Therapeutics (ESPR) Shares Bought by Columbus Circle Investors

Columbus Circle Investors raised its holdings in shares of Esperion Therapeutics (NASDAQ:ESPR) by 192.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 254,704 shares of the biopharmaceutical company’s stock after purchasing an additional 167,675 shares during the quarter. Columbus Circle Investors owned 0.95% of Esperion Therapeutics worth $18,423,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Ontario Teachers Pension Plan Board bought a new stake in shares of Esperion Therapeutics during the fourth quarter worth $1,635,000. Amundi Pioneer Asset Management Inc. lifted its position in shares of Esperion Therapeutics by 25.5% during the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 238,384 shares of the biopharmaceutical company’s stock worth $15,695,000 after purchasing an additional 48,485 shares during the last quarter. Sectoral Asset Management Inc bought a new stake in shares of Esperion Therapeutics during the fourth quarter worth $1,536,000. American Century Companies Inc. bought a new stake in shares of Esperion Therapeutics during the fourth quarter worth $1,604,000. Finally, Deutsche Bank AG lifted its position in shares of Esperion Therapeutics by 49.0% during the fourth quarter. Deutsche Bank AG now owns 175,787 shares of the biopharmaceutical company’s stock worth $11,571,000 after purchasing an additional 57,800 shares during the last quarter. Institutional investors and hedge funds own 91.38% of the company’s stock.

Several analysts have recently weighed in on ESPR shares. BidaskClub downgraded Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, March 20th. Credit Suisse Group decreased their price objective on Esperion Therapeutics from $108.00 to $73.00 and set an “outperform” rating for the company in a report on Friday, May 4th. Citigroup downgraded Esperion Therapeutics from a “buy” rating to a “neutral” rating and lifted their price objective for the company from $77.00 to $96.00 in a report on Monday, January 22nd. Northland Securities lifted their price objective on Esperion Therapeutics from $100.00 to $121.00 and gave the company a “buy” rating in a report on Thursday, April 19th. Finally, Chardan Capital lifted their price objective on Esperion Therapeutics from $75.00 to $100.00 and gave the company a “neutral” rating in a report on Tuesday, March 27th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $89.08.

In other news, Director Roger S. Newton sold 25,000 shares of the business’s stock in a transaction dated Thursday, March 29th. The stock was sold at an average price of $72.37, for a total transaction of $1,809,250.00. Following the sale, the director now owns 639,682 shares in the company, valued at $46,293,786.34. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 32.50% of the stock is currently owned by insiders.

Shares of ESPR stock opened at $42.78 on Friday. Esperion Therapeutics has a fifty-two week low of $40.52 and a fifty-two week high of $41.54.

Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings results on Wednesday, May 2nd. The biopharmaceutical company reported ($1.73) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.56) by ($0.17). During the same period last year, the firm posted ($1.80) earnings per share. equities research analysts predict that Esperion Therapeutics will post -5.94 earnings per share for the current year.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.

Want to see what other hedge funds are holding ESPR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Esperion Therapeutics (NASDAQ:ESPR).

Institutional Ownership by Quarter for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit